Researchers also figured out the combination therapy of CXCL9/10 agonists and immunotherapy drugs improved the overall response rate in metastatic melanoma (Ribas et al., 2021) and epithelial ovarian cancer (Orr et al., 2022). Here, CXCL9 is linked to metastatic melanoma.